Datametrex AI Limited's Profile

Datametrex signed agreement with major worldwide media & entertainment company for COVID-19 testing and related services. The company anticipates that the aggregate dollar amount of revenue under this agreement is expected to be over CAD $20MM for the initial nine months.
Datametrex AI Limited
Symbol
DM
Exchange
TSX-V
Shares
292,769,034 as of 03/31/2021
Industry
Technology & Medical
Website
Create a Post

Top Members

TREASURER
Last Posted:
03/23/2021
Rating:
Messages:
133
ADMINISTRATOR
Last Posted:
06/17/2021
Rating:
Messages:
143
MAIL ROOM
Last Posted:
0/0/0000
Rating:
Messages:
0
MAIL ROOM
Last Posted:
0/0/0000
Rating:
Messages:
0
MAIL ROOM
Last Posted:
0/0/0000
Rating:
Messages:
0

Datametrex AI Limited's Bulletin

Toronto, Ontario--(Newsfile Corp. - September 10, 2021) - Datametrex AI Limited (DM: TSXV) (D4G: FSE) (DTMXF: OTCQB) (the "Company" or "Datametrex") is pleased to announce that it has signed two new service agreements and commenced on September 3rd, 2021, (the "Agreements") for COVID-19 testing, one with a major Hollywood film studio and the other with one of the largest streaming platforms and services company. As of today's date, the Company is currently working with 24 production companies Canada wide. Film and TV productions in Canada and the United States, including unions representing production staff, film crews and actors along with Canadians in general, have a foremost concern regarding the Delta variant (B.1.617.2. variant), a hyper-contagious SARS-CoV-2 virus strain first identified in India in October 2020. "These agreements will help Datametrex continue to grow the testing business and generate revenue and profits for the shareholders while supporting the film industry in Canada," said Marshall Gunter, CEO of the Company. About Datametrex Datametrex AI Limited is a technology-focused company with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex's mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, Company provides progressive solutions to support the supply chain. For additional information on Datametrex and other corporate information, please visit the Company's website at www.datametrex.com. For further information, please contact: Marshall Gunter - CEOPhone: (514) 295-2300Email: mgunter@datametrex.com Neither the TSX Venture Exchange nor it's Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements: All statements included in this press release that address activities, events, or developments that the Company expects, believes, or anticipates will or may occur in the future are forward-looking statements. These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections, and other forward-looking statements will prove inaccurate, certain of which are beyond the Company's control. In particular, there is no guarantee that the parties will successfully negotiate and enter into a definitive agreement on mutually acceptable terms or complete the Transaction in the manner contemplated herein, if at all, that the due diligence of any of the parties will be satisfactory, or that the parties will obtain any required board, shareholder, third-party and/or regulatory or other governmental approvals, if any. Readers should not place undue reliance on forward-looking statements. Except as required by law, the Company does not undertake to revise or update these forward-looking statements after the date hereof or revise them to reflect the occurrence of future unanticipated events.
Toronto, Ontario--(Newsfile Corp. - August 30, 2021) - Datametrex AI Limited (DM: TSXV) (D4G: FSE) (DTMXF: OTCQB) (the "Company" or "Datametrex") is pleased to announce that it has signed two (2) new service agreements for COVID-19 testing in Montreal with two Hollywood feature-length films. The hyper-infectious Delta variant, which is significantly more contagious than the original variant of COVID-19, has been detected around 100 countries globally and is now the dominant variant worldwide, according to the US Centers for Disease Control. As previously mentioned, Film and TV productions in Canada including unions representing production staff, film crews and actors along with Canadians in general, have a foremost concern regarding the Delta variant (B.1.617.2. variant), a hyper-contagious SARS-CoV-2 virus strain, which was first identified in India in October 2020. Datametrex will continue to support Vancouver, Toronto, and Montreal in providing critical COVID-19 testing kits for actors, film crews, and production support staff to prevent cluster outbreaks. Film and TV production companies all support continued use of safety protocols, especially COVID-19 testing to keep production members and actors healthy and safe while employed on sets and in production offices. "The COVID-19 testing market in Montreal and across our network is an important business segment for Datametrex and we look to remain steadfast is supporting the film industry with COVID testing and now with the Delta variant of the virus now the dominant variant worldwide, it is right time to continue testing protocols to keep everyone working and continuing to stay healthy," stated Marshall Gunter, CEO of Datametrex. About Datametrex Datametrex AI Limited is a technology-focused company with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex's mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, Company provides progressive solutions to support the supply chain. For additional information on Datametrex and other corporate information, please visit the Company's website at www.datametrex.com. For further information, please contact: Marshall Gunter - CEOPhone: (514) 295-2300Email: mgunter@datametrex.com Neither the TSX Venture Exchange nor it's Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements:All statements included in this press release that address activities, events, or developments that the Company expects, believes, or anticipates will or may occur in the future are forward-looking statements. These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections, and other forward-looking statements will prove inaccurate, certain of which are beyond the Company's control. In particular, there is no guarantee that the parties will successfully negotiate and enter into a definitive agreement on mutually acceptable terms or complete the Transaction in the manner contemplated herein, if at all, that the due diligence of any of the parties will be satisfactory, or that the parties will obtain any required board, shareholder, third-party and/or regulatory or other governmental approvals, if any. Readers should not place undue reliance on forward-looking statements. Except as required by law, the Company does not undertake to revise or update these forward-looking statements after the date hereof or revise them to reflect the occurrence of future unanticipated events.
Toronto, Ontario--(Newsfile Corp. - August 26, 2021) - Datametrex AI Limited (DM: TSXV) (D4G: FSE) (DTMXF: OTCQB) (the "Company" or "Datametrex") is pleased to announce that the Company has entered into a $250,000 contract with a Canadian tech company on an Artificial Intelligence ("AI") contract and received the first 50% payment on August 23. Under the contract, the Company will be deploying its Nexology AI, Nexa Inteligence, that will allow for deepened analysis and understanding of social media influencers related to crypto assets including altcoins. Nexa lnteligence is a social-media discovery and monitoring platform for those who need to extract actionable insights out of discussions to inform decision-making. The system collects and analyses data from Twitter, Facebook, Tumblr, blogs, web forums, online news sites, Google Alerts and RSS feeds. With it, you'll be able to make qualitative analyses based on both quantitative and qualitative data. Many investor eyes have turned to the subject of crypto on social media which can have impact on crypto markets and the price rise of a specific coin, sometimes even despite poor business indicators. Companies are looking to find these influencers to engage and an get an understanding of conversation sediment around Bitcoin and altcoins. Social media is designed specifically to attract to whoever is reading it with algorithms, so when one sees a post from people who are like them, and speak in a way they can relate to, and they can join in the conversation, so they feel closer to the subject. This creates a problem as anyone can set themselves up as a financial influencer or finfluencer. In April of this year, the United Kingdom's Financial Conduct Authority ("FCA") warned social media sites that it may take action if they continue to allow the promotion of risky, and sometimes fraudulent, investments in crypto to inexperienced investing consumers. "Companies are looking to AI to help connect there business to their services by getting a leg up on who is saying what on social media and pinpointing and summarizing crypto winners and losers and the meaning of conversations without human being input, but tapping AI," stated Marshall Gunter, CEO of Datametrex. About Datametrex Datametrex AI Limited is a technology-focused company with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex's mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, Company provides progressive solutions to support the supply chain. For additional information on Datametrex and other corporate information, please visit the Company's website at www.datametrex.com. For further information, please contact: Marshall Gunter - CEO Phone: (514) 295-2300 Email: mgunter@datametrex.com Neither the TSX Venture Exchange nor it's Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements: All statements included in this press release that address activities, events, or developments that the Company expects, believes, or anticipates will or may occur in the future are forward-looking statements. These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections, and other forward-looking statements will prove inaccurate, certain of which are beyond the Company's control. In particular, there is no guarantee that the parties will successfully negotiate and enter into a definitive agreement on mutually acceptable terms or complete the Transaction in the manner contemplated herein, if at all, that the due diligence of any of the parties will be satisfactory, or that the parties will obtain any required board, shareholder, third-party and/or regulatory or other governmental approvals, if any. Readers should not place undue reliance on forward-looking statements. Except as required by law, the Company does not undertake to revise or update these forward-looking statements after the date hereof or revise them to reflect the occurrence of future unanticipated events. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/94366 Source: Newsfile Corp. (August 26, 2021 - 3:00 AM EDT) News by QuoteMedia www.quotemedia.com
Toronto, Ontario--(Newsfile Corp. - August 16, 2021) - Datametrex AI Limited (DM: TSXV) (D4G: FSE) (DTMXF: OTCQB) (the "Company" or "Datametrex") is pleased to report record financial results. In the second quarter the Company achieved the highest net income and revenue in it's history. The Company reported net earnings of $10,410,485 in the six months end June 30, 2021 on revenue of $29,494,191. The Company finished the second quarter with cash of $10,555,375 and marketable securities of $2,486,962. Datametrex has filed on SEDAR its financial statements ("FS") and related management discussion and analysis ("MD&A") for the six-month financial results ending June 30, 2021 ("Q2 2021"). All currency is in Canadian dollars unless otherwise stated. Q2 2021 Financial Summary Financial Highlights for six-month ended June 30, 2021 (Q2): Revenue of $29,494,191 for compared to revenue of $2,763,796. Net earnings of $10,410,485 compared to ($1,590,239). EBITDA of $12,250,211 compared to ($1,197,679). Cash balance significantly increased to $10,555,375 from $1,971,987 end of 2020. The following is financial information for the three-month financial results ending June 30, 2021, along with comparative results. Please refer to the Q2 2021 Filing in its entirety, which is available under Datametrex's profile at www.sedar.com. "We are very pleased with the achievements and the financial results we have delivered over the first half of 2021, and remain optimistic in our outlook as we move through the remainder of 2021. We also continue to expect greater profitability and notable cash flow driven by COVID-19 testing and the integration of Medi-Call, a multi-year strategic initiative undertaken as part of our post-pandemic world," commented Marshall Gunter, CEO of Datametrex. Financial Highlights for three-month ended June 30, 2021 (Q2):   Q2 2021 Q2 2020 % Change Total revenues $10,448,303 $1,954,394 434.6% Income/Loss before income taxes $1,034,941 ($868,478) 219.2% Net Income/Loss $850,134 ($868,478) 197.9% Income per share - basic $0.003 ($0.003) 200% EBITDA $1,565,957 ($669,376) 333.9% * Note: EBITDA ( non- IFRS measures) is calculated as Net Loss adjusted for 1. Income taxes, 2. Depreciation and amortization, and 3. Interest and accretion. Non-IFRS financial measures do not have standardized meanings prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Specific items may only be relevant in certain periods. For a reconciliation of non-IFRS financial measures please refer to the Company's Management Discussion and Analysis for the six months ended June 30, 2021.   Q2 2021 Q2 2020 Dollar Change Percent Change Total Assets $38,196,360 $8,677,434 $29,518,926 340.2% Total Liabilities $7,083,159 $4,677,405 $2,405,754 51.4%  Q2 Highlights and Subsequent Events On August 4, 2021, Datametrex announced it had passed the second round of scrutiny in a Canadian AI bid. The value of the contract is approximately $40 million. The binding bid remains subject to meeting all criteria on technical merit and ability to deliver in accordance with the bid procedures and deadlines. In June, the Company completed the acquisition of Medi-Call Inc. ("Medi-Call") by acquiring 100% of the issued and outstanding share capital of the company, an arm's length privately held company, incorporated under the laws of the Province of British Columbia. As a result of the acquisition, Medi-Call is now a wholly-owned subsidiary of the Datametrex. Medi-Call is a telemedicine company that is a subscription service that connects patients with providers or doctors in real time. Datametrex is integrating its platform into the Company's core AI technology. The Company announced, May 27, 2021, new sales revenue from Incheon International Airport Corporation and the Shinhan Financial Group, located in Seoul, South Korea. In April 2021, the Company's common shares began trading on the OTCQB under the stock symbol "DTMXF". The Company remains approximately a 10% shareholder of Graph Blockchain Inc. (GBLC: CSE). Outlook Despite a significant market slowdown due to the pandemic, the Company continued to improve its balance sheet in Q2. The Company continues focusing its resources on expanding and improving its AI business in 2021, with the Company expecting to see significant growth in both its existing cybersecurity AI verticals and new health technology verticals that the Company is building on. Unfortunately even with populations being vaccinated, and as the contagious Delta variant continues to circulate, there is clear and mounting evidence that people are coming down with breakthrough COVID-19 infections. Testing, contact tracing is a COVID-19 preventative action that will continue for years to come. Only 29.6% of the world population has received at least one dose of a COVID-19 vaccine, and a mere15.2% is fully vaccinated. As Datametrex further integrates Concierge Medical Consultants Inc's business, the Company sees a significant upside as the pandemic shows signs that patients are moving to healthcare being administered at home. Given the surge in the need for additional healthcare resources, establishing alternative healthcare options becomes critical. Datametrex understands that non-acute healthcare can mitigate exposing patients and their families to COVID-19. The Company is exploring deploying a variety of audio and video technology powered by its battle-tested AI technology to expand telemedicine services. "I am extremely proud of our whole team. We continue to experience growth as a result of our growing portfolio of companies. The future prospects of Datametrex continue to improve with our swelling customer base. We look forward to executing our business plan for the remainder of the fiscal year," commented Andrew Ryu, Chairman of the Company. About Datametrex Datametrex AI Limited is a technology-focused company with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex's mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, the Company provides progressive solutions to support the supply chain. For additional information on Datametrex, please visit the Company's website at www.datametrex.com. About Medi-Call Inc. Medi-Call is an enhanced telemedicine company providing technology-driven e-health or m-health care services including prescriptions, launching initially in British Columbia, and then expanding across Canada. The objectives of Medi-Call, include making health care accessible to people who live in rural and isolated communities and make services more readily available or convenient for people with limited time, mobility, or transportation choices. Medi-Call is driven to improve coordination and communication of treatment among members of a health care team and its patients. For additional information on Medi-Call and other corporate information, please visit the Company's website at www.medicallmd.ca/. For further information, please contact:Marshall Gunter - CEOPhone: (514) 295-2300Email: mgunter@datametrex.com Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release. Forward-Looking Statements: All statements included in this press release that address activities, events, or developments that the Company expects, believes, or anticipates will or may occur in the future are forward-looking statements. These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections, and other forward-looking statements will prove inaccurate, certain of which are beyond the Company's control. Readers should not place undue reliance on forward-looking statements. Except as required by law, the Company does not undertake to revise or update these forward-looking statements after the date hereof or revise them to reflect the occurrence of future unanticipated events. NON-IFRS FINANCIAL MEASUREMENTS The Company has included non-IFRS performance measures throughout this press release, including (a) Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA"); (b) Adjusted EBITDA which is EBITDA adjusted for the gain (loss) on change in fair value of the Company's investment properties and the gain (loss) on change in fair value of derivative instruments; and (c) Book Value per Share which is calculated as equity attributable to Datametrex AI Limited shareholders divided by total common shares outstanding at the end of the reporting period. These non-IFRS financial measurements do not have any standardized meaning as prescribed by International Financial Reporting Standards ("IFRS") and are therefore unlikely to be comparable to similar measures presented by other issuers. Accordingly, these performance measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. Management uses EBITDA metrics to measure the profit trends of the business units and segments in the consolidated group since it eliminates the effects of financing decisions. Certain investors, analysts and others utilize these non-IFRS financial metrics in assessing the Company's financial performance. These non-IFRS financial measurements have not been presented as an alternative to net income or any other financial measure of performance prescribed by IFRS. Reconciliation of non-IFRS measures has been provided throughout the Company's MD&A, as applicable, filed under the Company's profile on www.SEDAR.COM.